Market Cap 655.09M
Revenue (ttm) 0.00
Net Income (ttm) -59.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 858,900
Avg Vol 947,516
Day's Range N/A - N/A
Shares Out 57.26M
Stochastic %K 72%
Beta 0.09
Analysts Strong Sell
Price Target $20.85

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
focafoca99
focafoca99 Jun. 12 at 8:52 PM
$CLYM structured an Open Market Sale Agreement with Jefferies to sell up to $100 million of common stock, and also terminated its prior
0 · Reply
Quantumup
Quantumup Jun. 11 at 5:17 PM
BTIG⬆️ $CLYM's PT to $20 (was $19),⬆️budoprutug in ITP to 65% while reiterating at Buy $SNY NVS $AMGN VERA VRTX NVS TVTX OTSKY Here's what BTIG said in its note: https://x.com/Quantumup1/status/2065120495209484563?s=20
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 11 at 12:37 PM
$CLYM (+6.0% pre) Climb Bio reports initial phase 1b data for budoprutug in blood disorder https://ooc.bz/l/104829
0 · Reply
focafoca99
focafoca99 Jun. 11 at 11:23 AM
$CLYM outlined early Phase 1b/2a data showing budoprutug boosted platelet counts and achieved >90% B‑cell depletion in ITP patients.
0 · Reply
Invest2live
Invest2live Jun. 8 at 10:45 PM
$CLYM 596% already; congrats 🔆🌷🌟 Checkout $RXRX and $HUMA ; do your DD and get in.
0 · Reply
notreload_ai
notreload_ai Jun. 8 at 4:40 PM
Guggenheim gives $CLYM a Buy rating & $35 target. Their drug budoprutug deeply kills B-cells (like Amgen’s Uplizna) for autoimmune diseases, focusing on rare kidney conditions.
0 · Reply
Quantumup
Quantumup Jun. 8 at 10:59 AM
Guggenheim🏁 $CLYM and said: We are initiating coverage of Climb Bio, Inc. (CLYM) with a Buy rating and $35 PT. $AMGN VERA VRTX NVS TVTX $OTSKY Here's what Guggenheim went on to say: https://x.com/Quantumup1/status/2063938271806177684?s=20
0 · Reply
Ramanda87
Ramanda87 Jun. 5 at 2:02 PM
$CLYM should see $16 soon if Trump doesn’t make things worst if that’s possible…
0 · Reply
lowInCash
lowInCash Jun. 3 at 1:20 PM
$CLYM Glasgow conference starts today? I check today bulletin but no info about clym What numbers are you expecting?
0 · Reply
StockConsultant
StockConsultant Jun. 2 at 1:26 PM
$CLYM Climb Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?CLYM Breakout trade WATCH for possible breakout above 12.61 Target: 15.75, 33.5% Stop: 10.75 Loss: 8.9% P/L ratio: 3.8 : 1 - Excellent BULLISH [Timing] Extreme bullish 1 day moneyflow [Timing] breakout watch above 12.61, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
0 · Reply
Latest News on CLYM
Climb Bio price target raised to $20 from $19 at BTIG

2026-06-11T16:26:43.000Z - 3 days ago

Climb Bio price target raised to $20 from $19 at BTIG


Climb Bio initiated with a Buy at Guggenheim

2026-06-08T11:16:29.000Z - 6 days ago

Climb Bio initiated with a Buy at Guggenheim

AMGN


Climb Bio Registration statement: Registration filing

May 29, 2026, 8:00 AM EDT - 16 days ago

Climb Bio Registration statement: Registration filing


Climb Bio to Present at Upcoming Investor Conferences

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Climb Bio to Present at Upcoming Investor Conferences


Climb Bio price target raised to $17 from $15 at Wedbush

2026-05-08T13:46:05.000Z - 5 weeks ago

Climb Bio price target raised to $17 from $15 at Wedbush


Climb Bio reports Q1 EPS (20c), consensus (31c)

2026-05-07T15:52:43.000Z - 5 weeks ago

Climb Bio reports Q1 EPS (20c), consensus (31c)


Climb Bio Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Climb Bio Earnings release: Q1 2026


Climb Bio Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Climb Bio Quarterly report: Q1 2026


Climb Bio price target raised to $21 from $12 at Baird

2026-05-07T09:22:57.000Z - 5 weeks ago

Climb Bio price target raised to $21 from $12 at Baird


Climb Bio price target raised to $19 from $8 at BTIG

2026-05-07T07:48:54.000Z - 5 weeks ago

Climb Bio price target raised to $19 from $8 at BTIG


Climb Bio initiated with a Buy at Chardan

2026-05-05T08:06:20.000Z - 5 weeks ago

Climb Bio initiated with a Buy at Chardan


Climb Bio management to meet with Piper Sandler

2026-04-28T14:37:14.000Z - 6 weeks ago

Climb Bio management to meet with Piper Sandler


Climb Bio to sell 9.481M shares at $9.50 in private placement

2026-04-28T11:50:35.000Z - 6 weeks ago

Climb Bio to sell 9.481M shares at $9.50 in private placement


Climb Bio, Inc. Announces $110.0 Million Private Placement

Apr 28, 2026, 7:00 AM EDT - 6 weeks ago

Climb Bio, Inc. Announces $110.0 Million Private Placement


Climb Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

Climb Bio Proxy statement: Proxy filing


Climb Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

Climb Bio Proxy statement: Proxy filing


Climb Bio price target raised to $18 from $10 at Oppenheimer

2026-04-21T14:16:49.000Z - 7 weeks ago

Climb Bio price target raised to $18 from $10 at Oppenheimer


Climb Bio initiated with an Outperform at Mizuho

2026-04-15T08:50:39.000Z - 2 months ago

Climb Bio initiated with an Outperform at Mizuho


Climb Bio Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Climb Bio Proxy statement: Proxy filing


Climb Bio granted Fast Track Designation to budoprutug by FDA

2026-04-07T11:28:16.000Z - 2 months ago

Climb Bio granted Fast Track Designation to budoprutug by FDA


Climb Bio management to meet with Piper Sandler

2026-04-02T15:11:39.000Z - 2 months ago

Climb Bio management to meet with Piper Sandler


Climb Bio initiated with a Buy at B. Riley

2026-03-24T09:20:12.000Z - 2 months ago

Climb Bio initiated with a Buy at B. Riley


Climb Bio initiated with a Buy at Truist

2026-03-17T20:16:36.000Z - 3 months ago

Climb Bio initiated with a Buy at Truist


Climb Bio initiated with a Strong Buy at Raymond James

2026-03-10T20:10:45.000Z - 3 months ago

Climb Bio initiated with a Strong Buy at Raymond James


Climb Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 3 months ago

Climb Bio Transcript: Leerink Global Healthcare Conference 2026


Climb Bio Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Climb Bio Earnings release: Q4 2025


Climb Bio Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Climb Bio Annual report: Q4 2025


Climb Bio Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 3 months ago

Climb Bio Slides: Corporate presentation


Climb Bio Slides: Investor Presentation

Jan 8, 2026, 7:00 AM EST - 5 months ago

Climb Bio Slides: Investor Presentation


Climb Bio Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Climb Bio Earnings release: Q3 2025


Climb Bio Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Climb Bio Quarterly report: Q3 2025


Climb Bio Transcript: Status Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Climb Bio Transcript: Status Update


Climb Bio Press release: Status Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Climb Bio Press release: Status Update


Climb Bio Slides: Status Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Climb Bio Slides: Status Update


Climb Bio Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 4:20 PM EDT - 9 months ago

Climb Bio Transcript: Baird Global Healthcare Conference 2025


Climb Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 10:55 AM EDT - 10 months ago

Climb Bio Transcript: Cantor Global Healthcare Conference 2025


Climb Bio Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Climb Bio Quarterly report: Q2 2025


Climb Bio Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Climb Bio Earnings release: Q2 2025


Climb Bio Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Climb Bio Earnings release: Q1 2025


Climb Bio Quarterly report: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Climb Bio Quarterly report: Q1 2025


Climb Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Earnings release: Q4 2024

Mar 25, 2025, 11:30 AM EDT - 1 year ago

Climb Bio Earnings release: Q4 2024


Climb Bio Annual report: Q4 2024

Mar 25, 2025, 11:30 AM EDT - 1 year ago

Climb Bio Annual report: Q4 2024


Climb Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Climb Bio Transcript: Leerink Global Healthcare Conference 2025


Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

Climb Bio to be Added to the Nasdaq Biotechnology Index


Climb Bio Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Climb Bio Earnings release: Q3 2024


Climb Bio Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Climb Bio Quarterly report: Q3 2024


Climb Bio Registration statement: Registration Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Climb Bio Registration statement: Registration Filing


Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.


Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024


Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team


Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results


Climb Bio Quarterly report: Q2 2024

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Climb Bio Quarterly report: Q2 2024


Climb Bio Earnings release: Q2 2024

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Climb Bio Earnings release: Q2 2024


Climb Bio Registration statement: Registration Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Registration statement: Registration Filing


Climb Bio Proxy statement: Proxy Filing

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Proxy statement: Proxy Filing

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Proxy statement: Proxy Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Transcript: M&A Announcement

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Climb Bio Transcript: M&A Announcement


Climb Bio Slides: M&A Announcement

Apr 11, 2024, 8:30 AM EDT - 2 years ago

Climb Bio Slides: M&A Announcement


Climb Bio Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Climb Bio Annual report: Q4 2023


Climb Bio Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Climb Bio Quarterly report: Q1 2023


Climb Bio Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Climb Bio Earnings release: Q1 2023


Climb Bio Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Climb Bio Proxy statement: Proxy Filing


Climb Bio Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Climb Bio Proxy statement: Proxy Filing


focafoca99
focafoca99 Jun. 12 at 8:52 PM
$CLYM structured an Open Market Sale Agreement with Jefferies to sell up to $100 million of common stock, and also terminated its prior
0 · Reply
Quantumup
Quantumup Jun. 11 at 5:17 PM
BTIG⬆️ $CLYM's PT to $20 (was $19),⬆️budoprutug in ITP to 65% while reiterating at Buy $SNY NVS $AMGN VERA VRTX NVS TVTX OTSKY Here's what BTIG said in its note: https://x.com/Quantumup1/status/2065120495209484563?s=20
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 11 at 12:37 PM
$CLYM (+6.0% pre) Climb Bio reports initial phase 1b data for budoprutug in blood disorder https://ooc.bz/l/104829
0 · Reply
focafoca99
focafoca99 Jun. 11 at 11:23 AM
$CLYM outlined early Phase 1b/2a data showing budoprutug boosted platelet counts and achieved >90% B‑cell depletion in ITP patients.
0 · Reply
Invest2live
Invest2live Jun. 8 at 10:45 PM
$CLYM 596% already; congrats 🔆🌷🌟 Checkout $RXRX and $HUMA ; do your DD and get in.
0 · Reply
notreload_ai
notreload_ai Jun. 8 at 4:40 PM
Guggenheim gives $CLYM a Buy rating & $35 target. Their drug budoprutug deeply kills B-cells (like Amgen’s Uplizna) for autoimmune diseases, focusing on rare kidney conditions.
0 · Reply
Quantumup
Quantumup Jun. 8 at 10:59 AM
Guggenheim🏁 $CLYM and said: We are initiating coverage of Climb Bio, Inc. (CLYM) with a Buy rating and $35 PT. $AMGN VERA VRTX NVS TVTX $OTSKY Here's what Guggenheim went on to say: https://x.com/Quantumup1/status/2063938271806177684?s=20
0 · Reply
Ramanda87
Ramanda87 Jun. 5 at 2:02 PM
$CLYM should see $16 soon if Trump doesn’t make things worst if that’s possible…
0 · Reply
lowInCash
lowInCash Jun. 3 at 1:20 PM
$CLYM Glasgow conference starts today? I check today bulletin but no info about clym What numbers are you expecting?
0 · Reply
StockConsultant
StockConsultant Jun. 2 at 1:26 PM
$CLYM Climb Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?CLYM Breakout trade WATCH for possible breakout above 12.61 Target: 15.75, 33.5% Stop: 10.75 Loss: 8.9% P/L ratio: 3.8 : 1 - Excellent BULLISH [Timing] Extreme bullish 1 day moneyflow [Timing] breakout watch above 12.61, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
0 · Reply
Ramanda87
Ramanda87 Jun. 1 at 6:34 PM
$CLYM I’ve got a bit of a good dilemma… Im in at an average of $2.55/share. I liquidated 1/3rd of my shares in the past 30days around an average of $11 sale price in an effort to take some profits. I want to liquidate another 1/3rd of shares at $15 and let the rest ride past $20. Should I be more patient and hold beyond the $15 mark or should I be taking more profits now at $12 in the spirit of being up 370% ???
0 · Reply
JFais
JFais Jun. 1 at 5:48 PM
$CLYM 3x since January
0 · Reply
Ralphbeach
Ralphbeach Jun. 1 at 1:36 PM
$FOCL $CLYM $DRTS $ATOM.X $CADL Cutting edge stocks. FOCL not loaded under stocktwits yet. EDAP TMS Name change to FocalTherics today. Symbol FOCL Pivoting the business towards robotic focal therapy, with Extracorporeal shock wave lithotripsy. HIFU Platform, Highly intensity focused ultrasound. This is used to ablate prostate tissue. No surgery, no cutting. HIFU is a billion dollar market. Revenue: 74 million Float: 28 Million Cash : 15 Million Institutions hold 38% Q1 Record revenue. 78% Growth HIFU
0 · Reply
kubota2323
kubota2323 May. 27 at 11:52 PM
$CLYM shake that tree
0 · Reply
Quantumup
Quantumup May. 19 at 3:04 PM
Piper Sandler reiterated $CLYM Overweight; $23 after hosting a leading nephrologist and coming away bullish on CLYM116, w/ high PoS where upcoming HV data has the potential to unlock significant value. $VERA VRTX $OTSKY NVS AMGN TVTX Here's what Piper Sandler said in its note to investors: https://x.com/Quantumup1/status/2056752410710659495?s=20
0 · Reply
Cheezypuffs
Cheezypuffs May. 14 at 9:12 PM
$CLYM https://library.ehaweb.org/eha/2026/eha-2026/4208991/edgar.charles.budoprutug.a.low-fucosylated.anti-cd19.monoclonal.antibody.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DBudoprutug
0 · Reply
boomshiva
boomshiva May. 12 at 1:53 PM
$CLYM 👀
0 · Reply
Quantumup
Quantumup May. 12 at 12:13 PM
H.C. Wainwright⬆️ $CLYM's PT to $20/said: We draw investors' attention to the fact that Climb Bio is poised to have a catalyst-rich year, with multiple clinical milestones slated for achievement with both lead assets from its portfolio. $RHHBY $VERA BIIB VRTX H.C. Wainwright added—Enrollment is ongoing in the PrisMN Phase 2 primary membranous nephropathy (pMN) trial of Climb Bio's most advanced asset, budoprutug. PrisMN is a global open-label, dose-ranging Phase 2 study designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 development. Initial data from this trial is anticipated in 4Q26. We reiterate our Buy rating, while raising our 12-month price target to $20 from the prior $15 per share.
0 · Reply
Rockemsock
Rockemsock May. 11 at 2:50 PM
0 · Reply
dixiebull
dixiebull May. 11 at 1:42 PM
$CLYM 12.50 testing
0 · Reply
dixiebull
dixiebull May. 6 at 7:17 PM
$CLYM grind on
0 · Reply
RETAlerts
RETAlerts May. 5 at 8:13 PM
$CLYM consolidating nicely after the run. Clean support holding, no messy wicks below. Structure worth watching.
0 · Reply